FibroBiologics Q2 2024 Earnings Report

FibroBiologics EPS Results

• Actual EPS: -$0.09
• Consensus EPS: -$0.09
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

FibroBiologics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

FibroBiologics Announcement Details

• Quarter: Q2 2024
• Date: 8/7/2024
• Time: N/A
• Conference Call Date: Wednesday, August 7, 2024
• Conference Call Time: 7:30AM ET

FibroBiologics (NASDAQ:FBLG), Inc. (NASDAQ: FBLG) is a clinical-stage biotechnology company focused on developing novel therapeutics and imaging agents targeting fibroblast activation protein (FAP). The company’s proprietary platform is designed to modulate fibrotic and inflammatory processes that underlie a range of serious diseases, including oncology, cardiovascular disorders and degenerative conditions. By harnessing FAP’s unique expression profile, FibroBiologics aims to provide precision treatments that minimize off-target effects and improve patient outcomes.

FibroBiologics’ pipeline features both therapeutic and diagnostic candidates. Its lead therapeutic programs are being evaluated for the treatment of solid tumors and organ fibrosis, leveraging antibody–drug conjugates and small-molecule inhibitors that selectively bind to FAP-expressing cells. In parallel, the company is advancing radiolabeled imaging agents designed to visualize FAP distribution in vivo, potentially enabling earlier detection and more accurate monitoring of disease progression.

Founded in 2020 and headquartered in San Diego, California, FibroBiologics benefits from proximity to leading academic research centers and a vibrant biotech community. The company has established strategic partnerships with contract research organizations and academic institutions across North America and Europe to accelerate preclinical studies and scale up manufacturing. This global network supports FibroBiologics’ commitment to rigorous clinical development and regulatory compliance.

FibroBiologics is led by a management team with decades of combined experience in biotechnology, pharmaceutical development and regulatory affairs. The executive team has a track record of advancing novel therapies through clinical trials and securing global regulatory approvals. With its specialized focus on FAP-targeted approaches, FibroBiologics aims to address unmet medical needs in fibrosis and cancer, striving to bring transformative solutions to patients worldwide.